3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
2
Recurrence
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
44
Carboplatin
40
Cisplatin
36
Paclitaxel
29
Pemetrexed
24
Nivolumab
24
Gemcitabine
23
Dexamethasone
21
Rituximab
18
Ipilimumab
16
Cyclophosphamide
15
Fluorouracil
14
Capecitabine
14
atezolizumab
13
Docetaxel
13
trastuzumab deruxtecan
12
Trastuzumab
12
Lenalidomide
12
durvalumab
11
daratumumab
11
Cytarabine
11
olaparib
10
Prednisone
10
Bortezomib
10
Bevacizumab
10
130-nm albumin-bound paclitaxel
10
Doxorubicin
9
venetoclax
8
Oxaliplatin
8
Crizotinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Has announcements
×
dostarlimab
×
Clear all
NCT02715284
2026-01-13
GARNET
Tesaro, Inc.
Phase 1
Active not recruiting
730 enrolled
3 FDA
NCT03981796
2025-09-03
RUBY
Tesaro, Inc.
Phase 3
Active not recruiting
785 enrolled
2 FDA